Johnson & Johnson Achieves Phase 3 PFS Superiority with Talquetamab-Daratumumab Combination in Relapsed Myeloma

A Phase 3 readout from Johnson & Johnson is reshaping the bispecific antibody manufacturing calculus: MonumenTAL-3 data, presented at the 2026 European Hematology Association Annual Meeting and simultaneously published in The New England Journal of Medicine, confirm that talquetamab plus daratumumab with or without pomalidomide delivers statistically superior progression-free survival over standard-of-care DPd in relapsed or refractory multiple myeloma. For contract manufacturers and fill-finish operations already tracking J&J's bispecific pipeline, the commercial trajectory of a second approved combination regimen now looks considerably more concrete.

The trial reported a 24-month PFS rate of up to 81.3% versus 51.2% for DPd, and an overall survival rate of up to 89.2% versus 79.1%, representing a reduction in the risk of disease progression or death of up to 72.0% and a reduction in the risk of death of up to 53.0%. MonumenTAL-3 is the first Phase 3 study to demonstrate superior PFS with a GPRC5D-targeting bispecific antibody combination in earlier treatment lines, and it is the third positive Phase 3 result from J&J's bispecific portfolio within recent months.

From a biologics manufacturing standpoint, the mechanistic profile of talquetamab carries process implications worth noting. GPRC5D expression is independent of BCMA, and the antibody largely spares healthy B-cells, a selectivity profile that distinguishes it from earlier-generation myeloma biologics. Combining it with daratumumab, a CD38-targeting monoclonal antibody already manufactured at commercial scale, creates a dual-molecule regimen whose fill-finish and cold-chain requirements will demand validated co-administration protocols and, where applicable, separate batch release pathways under 21 CFR Part 211 and applicable ICH Q10 quality system frameworks.

The broader portfolio signal is operationally significant. Three positive Phase 3 bispecific studies in rapid succession indicate that J&J is moving toward earlier treatment-line positioning across its oncology pipeline, not consolidating around a single late-line indication. CDMOs and in-house biologics sites supporting this portfolio should anticipate demand planning reviews that account for expanded patient populations, longer treatment durations, and the formulation complexity inherent in bispecific antibody production.

Regulatory submissions based on the MonumenTAL-3 dataset have not yet been announced, but the simultaneous NEJM publication and EHA presentation position the data package for near-term filing review by health authorities in the EU and US.

Source: Johnson & Johnson via GlobeNewswire, June 13, 2026.